+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride



Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride



Drug Intelligence and Clinical Pharmacy 21(2): 183-186



The pharmacy and therapeutics committee-based clinical evaluation can be a useful tool in the economic and functional effectiveness of a restrictive formulary system. We utilized this concept to evaluate a generic formulation of procainamide hydrochloride (PA) for admission to our formularies. The study performed was a randomized, single-blind, crossover comparison of the serum-concentration profiles of two preparations (Squibb vs. Ascot) of conventional-release PA. Ten outpatients requiring chronic PA therapy for the control of ventricular dysrhythmias were evaluated. The resultant dose-adjusted data showed no significant difference between mean serum PA concentrations at any sample time, area under the serum concentration-time curves, mean peak serum PA concentrations achieved, or peak-trough fluctuations. Relative bioavailability was calculated to be 0.972 +/- 0.59. The Ascot preparation demonstrated a delay of 15 minutes before the onset of absorption; however, it also showed an earlier tmax in comparison to the Squibb formulation. Generic substitution of Ascot PA in place of Squibb PA may be implemented with significant cost savings.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039614304

Download citation: RISBibTeXText

PMID: 3829910


Related references

Comparable bioavailability between two preparations of procainamide hydrochloride. Drug Intelligence & Clinical Pharmacy 20(6): 451, 1986

Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients. Annals of Internal Medicine 98(5 Pt 1): 613-614, 1983

A comparison between microcrystalline and conventional phenytoin preparations: relative bioavailability and steady-state plasma concentrations. Journal of Neurology 223(4): 241-249, 1980

Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation. Schweizerische Medizinische Wochenschrift 110(39): 1415-1419, 1980

Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. Biopharmaceutics and Drug Disposition 8(5): 461-468, 1987

Prediction of steady-state trough serum procainamide concentrations after administration of a sustained-release procainamide preparation. Therapeutic Drug Monitoring 8(2): 184-188, 1986

Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. Asian Pacific Journal of Allergy and Immunology 19(2): 69-78, 2001

Serum concentration fluctuation and bioavailability comparison between indomethacin sustained-release and conventional capsules during steady state. Zhongguo Yao Li Xue Bao 13(4): 298-301, 1992

Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state. Schweizerische Medizinische Wochenschrift 112(47): 1702-1710, 1982

Comparative bio availability of immediate release and sustained release procainamide at steady state in cardiac patients. Clinical Research 31(2): 634A, 1983

Severe neutropenia associated with procainamide: comparison of sustained release and conventional preparations. American Heart Journal 109(6): 1393-1395, 1985

Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate. Clinical Therapeutics 5(4): 357-364, 1983

Steady state bio availability of a sustained release procainamide preparation. Drug Intelligence & Clinical Pharmacy 16(6): 475-476, 1982

Steady-state pharmacokinetic comparison of a one-a-day controlled-release hydromorphone hydrochloride capsule vs immediate-release hydromorphone hydrochloride tablet. Clinical & Investigative Medicine (Suppl. ): S22, 1998

Bioavailability of two retarded nifedipine preparations in steady state. Naunyn-Schmiedeberg's Archives of Pharmacology 345(Suppl. 1): R2, 1992